


Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. – 30. (Canceled)
31. (Currently amended) A compound according to formula I,



I

or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; ~~provided A is not a saturated alicyclic when X² is =N-, X³ is -O-, and A is a pyridin-4-yl;~~

R¹ is selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=O)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C₁₋₆ alkyl, aryl, aryl C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

two adjacent of R¹, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R¹⁰;

R² and R³, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R⁶;

each R⁴ is selected from -H; C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin-3-yl;

aryl; aryl C₁₋₆ alkyl; heterocyclyl; and heterocyclyl C₁₋₆ alkyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃;

two of R⁴, when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R⁵ is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

Y is =N- or =C(H);

X¹ and X² are each independently either =N- or =C(R⁹)-;

X³ is ~~selected from~~ N(R⁷)-, ~~O~~, and ~~S~~;


R⁷ is hydrogen;

each of R⁶ and R¹⁰ is independently selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, optionally substituted alkoxy, C₁₋₆ alkyl, aryl, aryl C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

two adjacent of R⁶, together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and

each R⁹ is independently selected from -H; halo; trihalomethyl; -CN; -NO₂; -OR⁴; -N(R⁴)R⁴; -S(O)₀₋₂R⁴; -SO₂N(R⁴)R⁴; -CO₂R⁴; -C(=O)N(R⁴)R⁴; -C(=NR⁵)N(R⁴)R⁴; -C(=NR⁵)R⁴; -N(R⁴)SO₂R⁴; -N(R⁴)C(O)R⁴; -C(=O)R⁴; alkoxy; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; provided when R⁹ is aryl, heteroaryl, -C(H)=C(H)R or -C(H)=NR, where R is an optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not =C(H)-.


32. (Previously presented) The compound according to claim 31, wherein the five- to six-membered ring formed by R^2 and R^3 is an aryl or a heteroaryl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
33. (Previously presented) The compound according to claim 32, wherein the five- to six-membered ring formed by R^2 and R^3 is phenyl or pyridyl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
34. (Previously presented) The compound according to claim 33, of formula **II**,



II;

- or a pharmaceutically acceptable salt or stereoisomer, thereof.
35. (Previously presented) The compound according to claim 34, wherein X^1 is $=C(R^9)-$, X^2 is $=N-$, X^3 is $-N(R^7)-$, and R^7 is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.
36. (Previously presented) The compound according to claim 35, wherein Y is $=N-$; or a pharmaceutically acceptable salt or stereoisomer, thereof.
37. (Previously presented) The compound according to claim 36, wherein A is either a six- to ten-membered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R^1 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
38. (Previously presented) The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms; and where A is substituted with 1-5 R^1 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.


39. (Previously presented) The compound according to claim 38, wherein R^1 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
40. (Previously presented) The compound according to claim 39, of formula **III**,



III

wherein R^7 is hydrogen and at least one of R^1 is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. (Previously presented) The compound according to claim 40, wherein the compound is either of Formula IIa or IIb:




or a pharmaceutically acceptable salt or stereoisomer, thereof.


42. (Previously presented) The compound according to claim 41, wherein R^9 is selected from -H; trihalomethyl; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

43. (Previously presented) The compound according to claim 42, wherein R^6 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, C₁₋₆ alkyl, heterocyclyl, heterocyclyl C₁₋₆ alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R⁶, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.
44. (Previously presented) The compound according to claim 43, wherein R^6 is selected from -H, halo, -OR⁴, -N(R⁴)R⁴, C₁₋₆ alkyl, heterocyclyl, heterocyclyl C₁₋₆ alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R⁶, together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.
45. (Previously presented) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin-3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃; or a pharmaceutically acceptable salt or stereoisomer, thereof.
46. (Previously presented) The compound according to claim 45, wherein at least one of R¹ is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
47. (Previously presented) The compound according to claim 46, wherein R⁹ is selected from -H, trihalomethyl, and C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
48. (Previously presented) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is heterocyclyl C₁₋₆ alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.

49. (Previously presented) The compound according to claim 48, wherein said heteroalicyclic is selected from the group consisting of dioxolanyl, piperidiny, piperaziny, 2-oxopiperaziny, 2-oxopiperidiny, 2-oxopyrrolidiny, 2-oxoazepiny, azepiny, 4-piperidony, pyrrolidiny, morpholiny, quinuclidiny, tetrahydrofuryl, tetrahydropyranly, thiamorpholiny, thiamorpholiny sulfoxide, 2,5-diazabicyclo[2.2.1]heptanyl, and thiamorpholiny sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.
50. (Currently amended) A compound according to Formula IIIa or IIIb,



IIIa



IIIb

each R^1 is independently selected from -H, halo trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

R⁹ is selected from -H, trihalomethyl; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidiny; aryl C₁₋₆alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆alkyl; and

wherein at least one of R⁶ is -OR⁴ and R⁴ is alkyl substituted with at least one additional of alkoxy, amino, dialkylamino, and monoalkylamino where the amino of the monoalkylamino is further substituted with *N*-methyl-pyrrolidin-3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with -NH₂, -NHCH₃, or -N(CH₃)₂; or a pharmaceutically acceptable salt or stereoisomer, thereof.

51. (Currently amended) The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

Table 3






Entry	Name	Structure
10	4-{7,8-bis(methoxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
12	4-(7,8-bis(methoxy)-1-{[4-(methoxy)phenyl]methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
13	4-{7,8-bis(methoxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
14	4-{7,8-bis(methoxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
15	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
20	4-[1-{[3,4-bis(methyloxy)phenyl]methyl}-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
21	4-(7,8-bis(methyloxy)-1-{[3-(methyloxy)phenyl]methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
22	4-[1-ethyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
25	4-[1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
27	4-[7,8-bis(methyloxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
28	4-[1-(1-methylethyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
29	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
31	4-[1-methyl-6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
32	4-[6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
34	4-[6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
35	4-[1-methyl-7,8,9-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
36	4-[1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
37	2-methyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
38	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-(methoxy)phenol	
39	4-{1-methyl-8-(methoxy)-7-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
40	2-(ethyloxy)-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
41	2-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
42	2-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
44	2-bromo-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
45	1-{[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]methyl}pyrrolidin-2-one	

Table 3

Entry	Name	Structure
54	4-{1-methyl-7-(methyloxy)-8-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
55	4-{1-methyl-8-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
58	4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
59	4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
60	4-[7-(ethyloxy)-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
61	4-{1-methyl-8-(methyloxy)-9-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
63	2-ethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
64	4-(1-methyl-8-(methyloxy)-9-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
65	4-(1-methyl-7-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
66	4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]piperidine-1-carboxylate	
69	2-chloro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
70	2-fluoro-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
71	2-methyl-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
72	2-bromo-4-[1-methyl-8,9-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3






Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
79	4-[6,9-difluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
80	2-bromo-4-{1-methyl-8-(methyloxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
81	2-chloro-4-{1-methyl-8-(methyloxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
82	4-(7,8-bis(methyloxy)-1-[[[(phenylmethyl)amino]methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
85	2,5-dichloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
87	2-bromo-4-(1-methyl-8-(methoxy)-9- {[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
88	2-chloro-4-(1-methyl-7-(methoxy)-8- {[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
89	4-[9-fluoro-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
90	4-(1-methyl-8-(methyloxy)-9- {[2-(methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	
91	2-chloro-4-(1-methyl-8- (methyloxy)-9- $\{[(1$ - methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	
92	4-[6-bromo-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
93	4-[6-fluoro-1-methyl-7,8- bis(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	
94	4-[9-chloro-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
95	2-chloro-4-[8- {[(1-ethylpiperidin-4-yl)methyl]oxy} -1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
96	3-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
97	4-(1-methyl-8,9-bis {[2-(methyloxy)ethyl]oxy} -3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
101	2-chloro-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
102	2-bromo-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
103	2-chloro-4-[1-methyl-8-({[1-(1-methylethyl)piperidin-4-yl]methyl}oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
104	4-[9-bromo-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
105	4-[7-chloro-9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
106	4-[8-{{(1-acetylpiperidin-4-yl)methyl}oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
107	4-[9-{{(1-acetylpiperidin-4-yl)methyl}oxy}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-bromophenol	
108	2-chloro-4-(1-methyl-9-(methyloxy)-8-{{[2-(methyloxy)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
109	4-[7-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
110	2-chloro-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
112	2-chloro-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
113	2-bromo-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
114	3-fluoro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
115	2-chloro-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
116	2-bromo-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3






Entry	Name	Structure
120	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
123	4-[9-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -benzo[<i>e</i>]indazol-5-yl]phenol	
125	3-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
126	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-3-fluorophenol	
127	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
130	3-fluoro-4-(1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
131	2-chloro-4-(1,7-dimethyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
134	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2-methylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
135	2-bromo-5-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
136	4-[7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
137	4-[7,8-bis(methoxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
138	4-{7,8-bis(methoxy)-1-[(methoxy)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}-2-chlorophenol	
139	2-chloro-4-(1-methyl-3 <i>H</i> -[1,3]dioxolo[4,5- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
142	2-chloro-4-[7-[(difluoromethyl)oxy]-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
143	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
144	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	

Table 3

Entry	Name	Structure
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinolin-7-yl)phenol	
147	2-chloro-4-[1-methyl-6,7,8-tris(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
148	2-bromo-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)-5-fluorophenol	
149	7-(3-chlorophenyl)-11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinoline	
150	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-8,9-dihydro-3H-[1,4]dioxino[2,3-g]pyrazolo[3,4-c]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
151	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydrofuran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
152	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
153	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2,2,2-trifluoroethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
154	2-chloro-5-fluoro-4-[9-fluoro-1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

Table 3

Entry	Name	Structure
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinoline	
157	2-chloro-4-{8-[(difluoromethyl)oxy]-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
158	2-chloro-4-(6,11-difluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	
159	4-(1-methyl-3 <i>H</i> -benzo[<i>e</i>]indazol-5-yl)phenol	
160	6-fluoro-7-(2-fluorophenyl)-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinoline	
161	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
162	2-chloro-4-[8-{[2-(ethyloxy)ethyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
164	3-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	
165	2-chloro-5-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
168	2-chloro-4-[9-ethyl-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
169	2-chloro-4-(6,9-difluoro-1-methyl-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
170	5-(3-chloro-4-hydroxyphenyl)-8-fluoro-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	
171	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
172	2-chloro-4-(6-fluoro-1-methyl-8,9-bis{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
173	5-[3-chloro-4-(methyloxy)phenyl]-6-fluoro-1-methyl-7-(methyloxy)-8- {[(1-methylpiperidin-4-yl)methyl]oxy }-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinoline	
174	5-[3-chloro-4-(methyloxy)phenyl]-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	
176	2-chloro-4- {6-fluoro-1-methyl-7-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl} phenol	
177	2-chloro-4-[8- {[2-(4-ethylpiperazin-1-yl)ethyl]oxy }-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
178	2-chloro-4-[8- {[2-(diethylamino)ethyl]oxy }-6-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
179	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
182	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
183	2-bromo-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
184	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
185	4-(6-fluoro-1-methyl-9-(methoxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-2-methylphenol	

Table 3

Entry	Name	Structure
186	2-chloro-4-{6,9-difluoro-1-methyl-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
188	2-chloro-4-(8-{[2-(diethylamino)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
193	5-(4-aminophenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
194	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
196	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
197	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
198	5-(6-aminopyridin-3-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
199	5-(5-amino-2-thienyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

Table 3

Entry	Name	Structure
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
201	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[3-(4-methylpiperazin-1-yl)propyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
203	N-[5-(6,9-difluoro-8-hydroxy-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-1,3-thiazol-2-yl]acetamide	
206	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3






Entry	Name	Structure
207	4-[8-({2-[butyl(ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-2-chlorophenol	
208	4-[8-{{[(2 <i>R</i>)-2-amino-3-methylbutyl]oxy}}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-2-chlorophenol	
209	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
210	2-chloro-4-[8-{{[(1-ethylpiperidin-4-yl)methyl]oxy}}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

Table 3

Entry	Name	Structure
213	4-[8-{{(2 <i>R</i>)-2-amino-3,3-dimethylbutyl}oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
214	2-chloro-4-[6-fluoro-1-methyl-9-(methoxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
215	2-chloro-4-[8-{{2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
216	2-chloro-4-[6-fluoro-1-methyl-8-({2-[4-(1-methylethyl)piperazin-1-yl]ethyl}oxy)-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
217	4-[8-{{2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	

Table 3

Entry	Name	Structure
218	2-chloro-4-[8-{[2-(1-ethylpiperidin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
219	2-chloro-4-[8-{[2-(diethylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
220	2-chloro-5-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
223	2-chloro-4-[6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
224	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
225	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
226	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methylamino)ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
228	2-chloro-4-[8-({2-[[2-(diethylamino)ethyl](methylamino)ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethylamino)ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
230	4-[8-[(2-{bis[3-(dimethylamino)propyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
231	2-chloro-4-[6-fluoro-1-methyl-8-(2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl)oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
232	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-{(2 <i>S</i>)-2-[(methyloxy)methyl]pyrrolidin-1-yl}ethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
233	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-pyrrolidin-1-yl)piperidin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
234	2-chloro-4-[8-{[2-(4-cyclohexylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
235	2-[4-(2-{[5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-yl]oxy}ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
237	2-chloro-4-[6-fluoro-1-methyl-8-{[2-(4-methyl-1,4-diazepan-1-yl)ethyl]oxy}-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
238	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3


Entry	Name	Structure
240	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
241	2-chloro-4-[8-{[2-(2,6-dimethylpiperidin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
242	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(octahydroquinolin-1(2 <i>H</i>)-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
243	4-[8-({2-[bis(1-methylethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
244	4-[8-[(2-{bis[2-(methyloxy)ethyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	

Table 3

Entry	Name	Structure
245	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl} phenol	

52. (Currently amended) A Compound selected from

9	4-[7,8-bis(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]benzene-1,2-diol	
19	4-[7,8-bis(methyloxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
24	4-[6,7,8-tris(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
26	4-[8-(methyloxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
-----	--	--

53. (Previously presented) A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.
54. (Previously presented) A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.
55. (Previously presented) The method according to claim 54, wherein the kinase is ALK.
56. (Previously presented) The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.
57. (Previously presented) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims 31.
58. (Previously presented) The method of claim 57 where the disease is an ALK-positive lymphomas, B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.